Ferring and IMAB Ink Contract for Potential IBD Therapy Olamkicept in Asia

Ferring and IMAB Ink Contract for Potential IBD Therapy Olamkicept in Asia
Ferring Pharmaceuticals and Shangai-based biotech IMAB signed a licensing agreement granting IMAB exclusive rights to olamkicept (pINN), a potential drug for inflammatory bowel disease (IBD), in Asia. Under the terms of the agreement, IMAB will have a Phase 2-ready asset with differentiated product profile. IMAB will be responsible for paying for additional product development, and will

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *